Orchid Pharma Limited share price

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins and injectable cephalosporins; human and veterinary products; and antibiotics, including beta-lactam. It serves pharma companies, generic drug manufacturers, healthcare distributors, and institutional and government buyers. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed i…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: ORCHPHARMAISIN INE191A01027

16 Oct 2026, 3:29 PM IST₹911.25▼ 16.80 (1.81%)

Market Cap₹ 4,622 Cr.
Current Price₹ 911.25
High / Low₹ 1,144 / 480
Stock P/E566.0
Book Value₹ 254
Dividend Yield0.00 %
ROCE1.1 %
ROE0.60 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 1.61
Price / Book3.59
OPM3.3 %
Debt / Equity0.20
Sales growth (5Y)12.5 %
Profit growth (5Y)—
Promoter holding133.6 %
EV / EBITDA94.2
Beta0.49
All-time high₹ 2,654

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
ORCHPHARMA	-4.83%	-15.54%	+61.08%	+20.07%	+25.07%	+23.40%	+15.28%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Orchid Pharma Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹4,622 crore.
It trades at 566.0 times its last 12 months' earnings and 3.6 times book value.
Revenue grew 12.5% a year over the last 5 years.
Return on equity was 0.6% and return on capital employed 1.1% in the latest year.
Debt was 0.20 times shareholders' equity.
The share price is 20.3% below its 52-week high and up 25.1% over one year.
Promoters and insiders hold about 133.6%; institutions about 17.0%.

Pros

Borrowings are moderate at 0.20 times shareholders' equity.

Cons

Return on equity has been low: 6.8% on average over the last 3 years.
Interest cover is thin: operating earnings are 2.4 times the interest cost.
Profit growth has been weak: -23.7% a year over the last 3 years.
Latest quarter (Jun 2026): profit fell 78% from a year ago.
Promoter holding has fallen by 2.56 points over 3 years, to 69.84%.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Orchid Pharma Limited

Employees: 1,169
Head office: Chennai

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Orchid Pharma	911.25	566.0	4,622	0.00	3	-78.38	304	75.89	1.1	0.6	3.59	3.3	0.20	133.60	811	12.5
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	786	-39.18	7,119	2.33	14.9	11.8	3.11	17.5	0.02	31.13	28,163	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 55 Co.	1,712.85	34.0	14,656	0.22	680	8.79	6,020	18.81	14.6	13.5	4.02	15.6	0.21	55.20	20,499	11.0

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	183	199	221	217	244	223	217	237	173	194	207	238	304
YOY Sales Growth %	39.65%	20.28%	38.08%	3.43%	33.61%	12.05%	-1.47%	9.39%	-29.25%	-13.10%	-4.64%	0.05%	75.89%
	161	175	185	188	212	192	191	209	159	195	206	211	290
Material Cost %	61%	62%	55%	59%	61%	59%	57%	58%	57%	68%	69%	64%	67%
Employee Cost %	9%	9%	9%	8%	9%	9%	10%	9%	12%	13%	12%	9%	9%
Other Expenses %	18%	18%	20%	20%	16%	18%	20%	21%	22%	19%	19%	16%	19%
Operating Profit	22	23	35	29	32	30	26	28	14	-1	2	27	14
OPM %	12%	12%	16%	13%	13%	14%	12%	12%	8%	-1%	1%	11%	5%
	2	8	8	13	8	8	8	4	11	11	6	7	2
Exceptional items											-7	1
Interest	6	4	4	3	3	3	4	4	3	4	3	3	2
Depreciation	8	8	9	8	8	9	9	9	9	9	9	9	11
Profit before tax	11	20	30	30	28	26	22	19	14	-3	-12	23	3
				-10%	-1%			0%				0%	3%
Current tax				0
Deferred tax				-3	-0			-0				0	0
	9	20	29	33	29	27	21	22	15	-6	-13	24	3
Profit from associates	-1	-0	-1	-1	1	1	-2	3	1	-2	-0	1	1
YOY Profit Growth %			287.92%	-44.27%	212.08%	37.53%	-29.41%	-32.35%	-49.20%	-121.01%	-160.71%	6.66%	-78.38%
EPS in Rs	1.85	4.30	6.18	6.81	5.79	5.37	4.10	4.40	2.94	-1.13	-2.49	4.69	0.54
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	183	199	221	217	244	223	217	237	173	194	207	238	304
YOY Sales Growth %	39.65%	20.28%	38.08%	3.43%	33.61%	12.05%	-1.47%	9.39%	-29.25%	-13.10%	-4.64%	0.05%	75.89%
	161	175	185	188	211	193	191	203	159	194	204	209	289
Material Cost %	61%	62%	55%	59%	61%	59%	57%	58%	57%	68%	69%	64%	67%
Employee Cost %	9%	9%	8%	8%	9%	9%	10%	9%	12%	12%	11%	8%	9%
Other Expenses %	18%	18%	20%	20%	16%	19%	20%	18%	22%	19%	19%	16%	19%
Operating Profit	22	24	36	29	33	30	26	34	14	-1	3	29	15
OPM %	12%	12%	16%	13%	14%	13%	12%	14%	8%	0%	1%	12%	5%
	2	8	7	13	8	8	10	6	16	15	11	13	10
Exceptional items											-7	1
Interest	6	4	4	3	3	3	4	4	3	4	3	3	2
Depreciation	8	8	9	8	8	9	9	9	9	9	9	9	11
Profit before tax	11	20	31	30	29	26	24	28	18	2	-6	31	12
				-11%
Deferred tax				-3
	11	20	31	33	29	26	24	28	18	2	-6	31	12
YOY Profit Growth %			353.98%	-48.84%	170.09%	26.60%	-21.74%	-16.09%	-37.47%	-91.29%	-124.36%	9.89%	-34.40%
EPS in Rs	5.28	4.40	6.42	6.86	5.74	5.05	4.71	5.49	3.59	0.44	-1.15	6.03	1.99
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	450	560	666	819	922	811	943
YOY Sales Growth %		24.33%	19.00%	23.05%	12.52%	-12.00%
	400	510	582	709	805	770	902
Material Cost %	51%	56%	58%	59%	59%	65%	67%
Employee Cost %	15%	11%	10%	8%	9%	11%	10%
Other Expenses %	23%	24%	20%	19%	19%	19%	18%
Operating Profit	50	50	84	111	117	41	41
OPM %	11%	9%	13%	14%	13%	5%	4%
	15	9	19	31	27	35	26
Exceptional items			39			-7	-7
Interest	51	32	32	16	15	13	12
Depreciation	109	87	55	33	35	35	38
Profit before tax	-95	-60	55	92	96	21	10
				-3%	0%	-1%	1%
Current tax				0
Deferred tax				-3	-0	-0
	-117	-2	46	92	100	21	9
Profit from associates			-2	-3	4	-1	-1
YOY Profit Growth %				98.99%	8.13%	-79.38%
EPS in Rs	-28.55	-0.48	11.35	19.06	19.65	4.05	1.61

Compounded Sales Growth

5 Years:: 13%
3 Years:: 7%
TTM:: 11%

Compounded Profit Growth

3 Years:: -24%
TTM:: -90%

Stock Price CAGR

5 Years:: 15%
3 Years:: 23%
1 Year:: 25%

Return on Equity

4 Years:: 7%
Last Year:: 1%

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	451	557	666	819	922	811	943
YOY Sales Growth %		23.58%	19.56%	23.05%	12.52%	-12.00%
	393	500	582	709	798	766	896
Material Cost %	51%	56%	58%	59%	59%	65%	67%
Employee Cost %	14%	11%	10%	8%	9%	11%	10%
Other Expenses %	22%	23%	20%	19%	18%	19%	18%
Operating Profit	58	57	84	111	124	45	46
OPM %	13%	10%	13%	14%	13%	6%	5%
	6	9	19	30	32	55	49
Exceptional items			39			-7	-7
Interest	51	32	32	16	15	13	12
Depreciation	109	87	55	33	34	36	38
Profit before tax	-96	-53	55	92	106	45	39
				-4%
Deferred tax				-3
	-117	-5	54	95	106	45	39
YOY Profit Growth %				74.85%	12.38%	-57.54%
EPS in Rs	-28.70	-1.18	13.28	19.59	20.99	8.91	7.31

Compounded Sales Growth

5 Years:: 12%
3 Years:: 7%
TTM:: 11%

Compounded Profit Growth

3 Years:: -6%
TTM:: -59%

Stock Price CAGR

5 Years:: 15%
3 Years:: 23%
1 Year:: 25%

Return on Equity

4 Years:: 7%
Last Year:: 1%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	41	51	60	60
Reserves	648	1,119	1,494	1,504
	331	135	154	307
Long term borrowings	149	120	10	185
Short term borrowings	183	14	143	117
	205	249	370	388
Trade payables	174	230	336	347
Current liabilities	372	260	509	491
Total Liabilities	1,225	1,554	2,077	2,258
	621	645	834	1,122
Gross block	1,258	1,314	1,613	1,935
Accumulated depreciation	637	669	779	813
Goodwill & intangibles	0	15	17	74
CWIP	48	26	127	430
	556	883	1,117	706
Inventories	229	149	457	372
Trade receivables	215	196	353	381
Cash & equivalents	23	4	21	7
Current assets	501	791	1,097	929
Total Assets	1,225	1,554	2,077	2,258

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	18	126	51	126
Profit for the year	46	92	135	10
Working capital changes	-79	-8	-95	71
Direct taxes paid	-0	1	-15	2
	-31	-312	-36	-277
Fixed assets purchased	-85	-65	-154	-390
Fixed assets sold	59		0	9
Investments purchased	-5		-0
Investments sold			93	104
	31	167	2	137
Proceeds from borrowings	173
Repayment of borrowings	-110	-209
Interest paid	-32	-5	-13	-10
Net Cash Flow	18	-19	17	-14
Free Cash Flow	-67	61	-102	-264

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	6.7%	9.9%	9.9%	0.6%
ROCE	—	10.3%	8.4%	8.6%	1.1%
Operating margin	—	4.5%	9.6%	9.0%	3.3%
Net margin	—	7.0%	11.3%	9.7%	0.8%
Debt / equity	—	0.48	0.12	0.10	0.20
Current ratio	—	1.35	3.04	2.16	1.89
Debtor days	—	118	87	93	114
Inventory days	—	210	109	183	158
Days payable	—	160	168	134	147
Cash conversion cycle	—	168	28	142	125
Working capital days	—	71	237	155	131

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 69.84%
FIIs 0.81%
DIIs 20.75%
Public 8.61%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	72.40%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%
	8.08%	4.14%	1.96%	1.42%	1.94%	2.53%	2.69%	1.40%	1.56%	1.17%	0.87%	0.81%
Foreign portfolio investors (Cat. I)	8.08%	4.11%	1.90%	1.28%	1.77%	2.17%	2.24%	1.34%	1.44%	1.12%	0.73%	0.71%
Foreign portfolio investors (Cat. II)		0.03%	0.06%	0.14%	0.17%	0.36%	0.45%	0.05%	0.12%	0.05%	0.14%	0.09%
	12.47%	14.50%	17.73%	18.93%	18.29%	18.99%	20.10%	19.43%	19.04%	19.39%	20.25%	20.75%
Mutual funds	9.76%	10.40%	15.18%	16.91%	16.78%	17.46%	18.79%	18.58%	18.04%	18.01%	19.43%	19.93%
Insurance companies		2.45%	0.94%	0.87%	0.81%	0.85%	0.60%	0.14%	0.14%	0.13%	0.09%	0.07%
Banks	0.12%	0.12%	0.11%	0.11%	0.12%	0.10%	0.06%	0.06%	0.06%	0.06%	0.06%	0.06%
Alternative investment funds	2.58%	1.54%	1.50%	1.04%	0.59%	0.59%	0.65%	0.65%	0.80%	1.18%	0.66%	0.69%
	7.06%	11.53%	10.47%	9.81%	9.93%	8.64%	7.38%	9.34%	9.57%	9.60%	9.05%	8.61%
Retail (up to ₹2 lakh)	3.14%	6.17%	5.88%	5.59%	6.13%	5.47%	4.47%	5.96%	5.99%	5.69%	5.71%	5.21%
HNIs (above ₹2 lakh)	0.71%	1.62%	1.56%	1.57%	1.46%	0.95%	0.64%	0.95%	1.04%	1.08%	0.86%	1.01%
NRIs	0.16%	0.28%	0.37%	0.27%	0.31%	0.28%	0.39%	0.42%	0.45%	0.44%	0.46%	0.45%
Bodies corporate	2.03%	2.57%	1.83%	1.70%	1.52%	1.42%	1.34%	1.49%	1.58%	1.87%	1.60%	1.58%
No. of Shareholders	29,197	36,931	36,720	34,695	36,363	34,158	34,303	39,827	38,155	35,709	35,118	33,433

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Orchid Pharma

Holder (above 1%)	Stake
Quant Small Cap FundMutual fund	6.83%
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK CONSUMPTION FUND AND 7 OTHERSMutual fund · see the fund house	4.60%
UTI SMALL CAP FUND AND 3 OTHERSMutual fund · see the fund house	3.46%
INVESCO INDIA CONTRA FUND AND 2 OTHERSMutual fund · see the fund house	2.87%
BANDHAN SMALL CAP FUND AND 5 OTHERSMutual fund · see the fund house	1.53%

As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 19.93% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 13 Sep 2012
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Orchid Pharma Limited

What is the share price of Orchid Pharma Limited today?

Orchid Pharma Limited (ORCHPHARMA) last traded at ₹911.25 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Orchid Pharma Limited?

About ₹4,622 crore at the latest price.

What is the P/E ratio of Orchid Pharma Limited?

About 566.0 times its earnings over the last 12 months.

Is Orchid Pharma Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Orchid Pharma Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Orchid Pharma Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Orchid Pharma Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Orchid Pharma

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Orchid Pharma Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next